DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jjcl6c/pharmapoint) has announced the addition of the "PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2023" report to their offering.
Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage, and all commercially available glaucoma therapies focus on lowering elevated intraocular pressure (IOP), a known risk factor for glaucoma development and progression.
The launch of fixed-dose combination (FDC) products, which combine drugs from these various classes, will continue to be a source of significant growth in this market.
The glaucoma market is about to enter a phase of new growth with the arrival of first-in-class drugs, such as Aerie's Rhopressa, Bausch & Lomb's Vesneo (latanoprost bunod), and Inotek's trabodenoson into the 7MM during the forecast period, which will generate additional growth in the global glaucoma market.
Key Questions Answered
- The glaucoma market has been dominated by prostaglandin analogue (PGA) drugs in the last decade. New classes of drugs are anticipated the reach the market within the forecast period. How will these change the position the PGA drugs hold during the forecast period? Will these drugs maintain their market dominance in 2023?
- The current late stage glaucoma pipeline is varied, with first-in-class drugs in development with innovative modes of action. Which of these will have the biggest impact on the market? What strategies are developers undertaking to penetrate this crowded and highly generic market? Will these fulfill any unmet needs?
Key Topics Covered:
1 List of Tables and List of Figures
3 Disease Overview
5 Disease Management
6 Competitive Assessment
7 Unmet Need and Opportunity
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
- Aerie Pharmaceuticals
- Inotek Pharmaceuticals
- Bausch & Lomb
- Kowa Company
For more information visit http://www.researchandmarkets.com/research/jjcl6c/pharmapoint